Bonovo Orthopedics Inc.
This article was originally published in Start Up
Executive Summary
East meets West in the orthopedics field with the establishment of Bonovo OrthopedicsI, an Arizona-based manufacturer and distributor of orthopedic products and services that is targeting the China market, with its estimated population of 1.3 billion. In addition to distributing products for Western companies, Bonovo Orthopedics manufactures and sells it own domestic line of spine, hip, and knee implants. The company also acts as an original equipment manufacturer in China for partnering firms.
You may also be interested in...
Start-Up Previews (03/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.
Start-Up Previews (03/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Treating Late-Stage Prostate Cancer," features profiles of AndroBioSys, Bellicum Pharmaceuticals, Colby Pharmaceuticals and Med Discovery. Plus these Start-Ups Across Health Care: AeonClad Biomedical, Arete Therapeutics, Bonovo Orthopedics and Thrasos Therapeutics.
China: The Wild, Wild East for Medical Devices
Every medical device company is asking, "How can we take advantage of emerging opportunities in China?" Given the country's economic and population booms--China is home to one fifth the world's population--many analysts expect its medical device market to shortly come into full bloom, enjoying a compound annual growth rate of 15% over the next 10 years from a base of approximately $10 billion in 2007. Fueling this growth are positive improvements in China's business climate, making China a much less risky place to do business. Multinational firms are forming alliances in China to help them reach an untapped 1.3 billion patient population, even as a new breed of venture capital-backed, Western-style Chinese companies begins to grab a home court advantage.